Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
February 28, 2022 16:05 ET
|
Biomea Fusion, Inc.
Phase I trial of BMF-219, an irreversible covalent menin inhibitor, is currently underway Plan to initiate trials of BMF-219 in up to seven solid and liquid tumor types and diabetes Plan to announce...
Biomea Fusion Announces Appointment of Steve Morris, M.D. as Chief Medical Officer
February 01, 2022 06:30 ET
|
Biomea Fusion, Inc.
Renowned physician-scientist’s groundbreaking work led to the discovery and characterization of multiple oncogenes, including anaplastic lymphoma kinase (ALK)Dr. Morris will lead clinical development...
Biomea Fusion Announces First Patient Dosed
January 25, 2022 08:30 ET
|
Biomea Fusion, Inc.
BMF-219 is the first irreversible covalent menin inhibitor to enter the clinicPhase I trial is enrolling patients with relapsed/refractory acute leukemias, including those with MLL1/KMT2A gene...
Biomea Fusion Announces Participation at the H.C. Wainwright 2022 BioConnect Conference
January 11, 2022 08:30 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Biomea Fusion Announces 2022 Clinical Development Plan to Initiate Studies in up to Seven Different Tumor Types and in Diabetes for BMF-219
January 10, 2022 08:30 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes
January 06, 2022 08:30 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of...
Biomea Fusion Moves into New Headquarters and Expands R&D Facility
January 04, 2022 13:30 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Biomea Fusion to Present at the 40th Annual J.P. Morgan Healthcare Conference
December 21, 2021 08:00 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Biomea Fusion to be added to NASDAQ Biotechnology Index
December 14, 2021 08:00 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Biomea Fusion to Participate in Two Upcoming Investor Conferences
November 10, 2021 14:00 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...